At EAN 2022, Cristina Tassorelli, Professor of Neurology, University of Pavia, Italy, discussed how in general, newer, migraine-specific drugs for symptom prevention are effective at reducing number of headache days within 1 or 2 weeks following initiation, or even sooner in some patients. This fast onset means a more rapid improvement in a patient’s quality of life. In patients where their prescribed medication takes a number of months until there is a preventative effect, the chance that they remain adherent is decreased.
EAN : European Academy of Neurology
Disclaimer: The video represent the opinion of the speaker. Lundbeck does not recommend the use of drugs outside of its registered indications. Please always consult the Summary of Product Characteristics.
BE-NOTPR-0308, approval date : 05.2023